Merck tops quarterly estimates as Keytruda powers sales growth
Keytruda delivered $8.366 billion in quarterly sales, helping Merck lift revenue guidance as investors eye the drug’s eventual patent expiration.
Merck posted second-quarter worldwide sales of $16.6 billion and lifted its full-year revenue forecast as Keytruda and Keytruda QLEX generated $8.366 billion, up 5% from a year earlier. The results again showed how heavily the drugmaker’s earnings power still leans on its cancer franchise, even as management tries to broaden the story beyond one blockbuster.
The company laid out the numbers on August 4 with Chairman and Chief Executive Officer Robert M. Davis, Chief Financial Officer Caroline Litchfield and research chief Dean Y. Li participating in the update. Merck’s presentation showed Keytruda remains the centerpiece of the quarter: the drug’s combined sales with Keytruda QLEX accounted for about half of total worldwide revenue, a reminder that one product still drives a disproportionate share of growth.
That concentration is powerful when sales are rising and dangerous when investors start looking ahead. Merck has already been forced to think about Keytruda’s longer-term economics, including the fact that the drug is expected to be part of government price setting in 2026. The company’s own second-quarter materials also pointed to a broad, diverse pipeline and said it would highlight key regulatory and clinical milestones, an acknowledgment that future growth has to come from elsewhere as the Keytruda era matures.
Robert M. Davis has argued that the pipeline can shoulder more of the load when Keytruda eventually loses exclusivity, and Merck has been signaling that transition for some time. That matters because the market does not just judge Merck on one quarter’s beat. It is watching whether the company can keep delivering while preparing for a post-Keytruda period that will test the durability of its oncology franchise and the rest of its portfolio.
For now, the second quarter was a clean win. Sales came in strong enough to support a higher revenue outlook, and Keytruda’s 5% year-over-year growth gave Merck another quarter of breathing room. But the same figures that pleased investors also underscored the strategic risk: the more Keytruda carries the company today, the more pressure rises on Merck’s pipeline to prove it can carry the next phase of growth.
This article was produced by Prism’s automated news system from verified source data, official records, and press releases, then run through automated quality and moderation checks before publishing. The system is built and supervised by the people who set the standards it runs under. Read our full AI policy.
Did this article answer your question?
